Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,682 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,682 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $253.74 on Thursday. The firm has a market cap of $32.73 billion, a PE ratio of -96.85 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The firm’s fifty day moving average is $272.32 and its 200-day moving average is $240.10. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the previous year, the business earned $1.15 EPS. The company’s revenue was down 33.3% on a year-over-year basis. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALNY. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $26,000. Huntington National Bank boosted its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth about $29,000. Washington Trust Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $42,000. Finally, True Wealth Design LLC lifted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ALNY shares. JPMorgan Chase & Co. increased their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. HC Wainwright reissued a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.